| pubmed-article:9541420 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9541420 | lifeskim:mentions | umls-concept:C0376387 | lld:lifeskim |
| pubmed-article:9541420 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9541420 | lifeskim:mentions | umls-concept:C0018823 | lld:lifeskim |
| pubmed-article:9541420 | lifeskim:mentions | umls-concept:C0064113 | lld:lifeskim |
| pubmed-article:9541420 | lifeskim:mentions | umls-concept:C2350529 | lld:lifeskim |
| pubmed-article:9541420 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9541420 | pubmed:dateCreated | 1998-6-18 | lld:pubmed |
| pubmed-article:9541420 | pubmed:abstractText | The objective of this study was to evaluate the effects of itraconazole as a first choice drug in the treatment of pulmonary aspergillosis in heart transplant recipients. Heart transplant recipients suffering from invasive pulmonary aspergillosis were included in this study. Group 1 included 4 patients treated with i.v. itraconazole (Janssen Pharmaceutica) 400 mg daily, as a first choice drug for 28 d. Itraconazole was discontinued and amphotericin-B was started before the 28th day if clinical or radiographic worsening was observed. Group 2 included 3 patients treated with amphotericin-B as a first choice drug. Itraconazole was discontinued in all patients of Group 1 after 12-26 d of treatment because of radiographic worsening (n = 3) or combined clinical and radiographic worsening (n = 1). Subsequent treatment with amphotericin-B resulted in improvement of all patients. On a 5-yr follow-up period no relapse of aspergillosis was observed in 3 of them. The fourth patient expired from cerebral hemorrhage. The 3 patients of Group 2 treated with amphotericin-B showed a gradual improvement, and all were doing well on a 2-yr follow-up. In conclusion, in our study population consisted of heart transplant recipients amphotericin-B was superior to itraconazole in the treatment of invasive pulmonary aspergillosis. | lld:pubmed |
| pubmed-article:9541420 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9541420 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9541420 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9541420 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9541420 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9541420 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9541420 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9541420 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9541420 | pubmed:issn | 0902-0063 | lld:pubmed |
| pubmed-article:9541420 | pubmed:author | pubmed-author:SaroglouGG | lld:pubmed |
| pubmed-article:9541420 | pubmed:author | pubmed-author:MoulopoulosS... | lld:pubmed |
| pubmed-article:9541420 | pubmed:author | pubmed-author:Stamatelopoul... | lld:pubmed |
| pubmed-article:9541420 | pubmed:author | pubmed-author:KostisE BEB | lld:pubmed |
| pubmed-article:9541420 | pubmed:author | pubmed-author:NanasJ NJN | lld:pubmed |
| pubmed-article:9541420 | pubmed:author | pubmed-author:Anastasiou-Na... | lld:pubmed |
| pubmed-article:9541420 | pubmed:author | pubmed-author:KontoyannisD... | lld:pubmed |
| pubmed-article:9541420 | pubmed:author | pubmed-author:Petrochilou-P... | lld:pubmed |
| pubmed-article:9541420 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9541420 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:9541420 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9541420 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9541420 | pubmed:pagination | 30-4 | lld:pubmed |
| pubmed-article:9541420 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:meshHeading | pubmed-meshheading:9541420-... | lld:pubmed |
| pubmed-article:9541420 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9541420 | pubmed:articleTitle | Itraconazole for the treatment of pulmonary aspergillosis in heart transplant recipients. | lld:pubmed |
| pubmed-article:9541420 | pubmed:affiliation | University of Athens, School of Medicine, Department of Clinical Therapeutics, Alexandra Hospital, Greece. | lld:pubmed |
| pubmed-article:9541420 | pubmed:publicationType | Journal Article | lld:pubmed |
